【摘要】： 目的 觀察過氧化物酶體增殖物激活受體γ(Peroxisome Proliferator-Activated Receptor gamma, PPARγ)激動劑局部應(yīng)用對鼠角膜的影響,判斷其藥物毒性。 方法 將PPARγ激動劑DK2配制成滴眼液,將0.1%,0.5%,1.0% PPARγ激動劑局部滴用于Wistar大鼠右眼,觀察眼局部改變和熒光素鈉染色情況,并按照制定的眼部刺激反應(yīng)評分標(biāo)準(zhǔn),評判其對眼部刺激性,并行角膜病理組織切片染色和ELISA檢測房水PPARγ濃度,綜合評價藥物安全性。 結(jié)果 藥物各組鼠眼部刺激反應(yīng)評分均為1-3分,角膜切片HE和免疫組化染色示角膜結(jié)構(gòu)完整,細(xì)胞無損傷浸潤。ELISA測得給藥后房水中PPARγ濃度明顯增加,且PPARγ的表達(dá)具有濃度依賴性,但0.5%,1.0%兩個給藥組之間差異無統(tǒng)計(jì)學(xué)意義(P0.05)。 結(jié)論 1.0%濃度的PPARγ激動劑DK2滴眼液對鼠眼無刺激,具有安全性。 目的 探討過氧化物酶體增殖物激活受體γ(Peroxisome Proliferator-Activated Receptor gamma, PPARγ)激動劑對大鼠角膜移植排斥反應(yīng)的影響。 方法 SD大鼠為供體,Wistar大鼠為受體,建立SD-Wistar大鼠同種異體穿透性角膜移植模型。隨機(jī)分A、B、C、D及E組,其中A組：對照組,術(shù)后予以無菌生理鹽水點(diǎn)眼；B組：0.1%DK2滴眼液組；C組：1.0%DK2滴眼液組；D組：DK2口服灌胃給藥組；E組：1.0%環(huán)孢霉素A(CsA))滴眼液組；F組：Wistar大鼠自體同基因移植對照組,術(shù)后生理鹽水點(diǎn)眼。術(shù)后定期對各組角膜植片進(jìn)行臨床觀察,以混濁、水腫、新生血管3項(xiàng)指標(biāo)作為臨床評估標(biāo)準(zhǔn),記錄排斥指數(shù)(RI)、新生血管指數(shù)(NI)、植片存活時間。實(shí)時定量熒光PCR檢測鼠角膜內(nèi)ICAM-1mRNA表達(dá),流式細(xì)胞學(xué)檢測各組大鼠頜下淋巴結(jié)MHC-Ⅱ、CD80的變化情況,免疫組織化學(xué)法檢測大鼠頜下淋巴結(jié)CD86的表達(dá)。酶聯(lián)免疫吸附試驗(yàn)(ELISA)檢測鼠房水中IL-10的含量。結(jié)果 A-E組的角膜植片平均存活時間為9.2±1.5d、10.1±1.8d、18.3±1.1d、20.1±1.6d、18.1±1.5d,F組植片存活時間至觀察期結(jié)束(28.0d)。除B組外,其他用藥組植片存活時間與A組比較,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。C、E組植片存活時間兩兩比較差異無統(tǒng)計(jì)學(xué)意義(P0.05),D組植片存活時間與C組相比較有統(tǒng)計(jì)學(xué)差異。術(shù)后第9d角膜植片ICAM-1 mRNA顯示,A、B組相對表達(dá)量明顯高于C、D、E、F組；頜下淋巴結(jié)免疫指標(biāo)檢測,流式細(xì)胞學(xué)結(jié)果顯示第9 dC、D、E組DC表面MHC-Ⅱ及CD80單陽性表達(dá)率低于對照A,B組(P0.05)；免疫組化染色顯示,第9d時A、B組淋巴結(jié)高表達(dá)CD86,而C、D、E、F組未見有明顯表達(dá),至術(shù)后18d,C、D、E組CD86表達(dá)明顯增加。ELISA檢測術(shù)后第3、9、18天各組大鼠房水IL-10含量較低,各組平均含量無明顯差異；第9 d后,隨著排斥反應(yīng)發(fā)生延遲,C、D、E組IL-10含量較A、B組增加,但變化幅度不大。結(jié)論 PPARγ激動劑能顯著延長大鼠角膜植片的存活時間,其抑制角膜移植免疫排斥反應(yīng)具有隨濃度增加效應(yīng),并且全身用藥效果強(qiáng)于局部滴用1.0%DK2滴眼液和1.0%環(huán)孢霉素A。PPARγ激動劑能有效抑制角膜植片炎性細(xì)胞浸潤和ICAM-1 mRNA的表達(dá),抑制局部淋巴結(jié)內(nèi)樹突狀細(xì)胞的聚集和遞呈功能,可能是其發(fā)揮抗排斥作用機(jī)制的一部分。 目的 探討過氧化物酶體增殖物激活受體γ(Peroxisome Proliferator-Activated Receptor gamma, PPARγ)激動劑對體外誘導(dǎo)培養(yǎng)的大鼠骨髓來源樹突狀細(xì)胞(dendritic cells,DCs)分化成熟及免疫活性影響,探討藥物對DCs表達(dá)TLR4的影響。 方法 用GM-CSF和IL-4體外定向誘導(dǎo)Wistar大鼠骨髓細(xì)胞分化成樹突狀細(xì)胞,①分別加入兩種不同的PPARγ激動劑DK2和馬來酸羅格列酮,與細(xì)胞共培養(yǎng)12-72h后,MTT法檢測樹突狀細(xì)胞生長抑制率,乳酸脫氫酶檢測法(LDH)比較兩種藥物的藥效；②細(xì)胞隨機(jī)分成4組,即空白對照組,陽性對照組(脂多糖,LPS),低濃度藥物組和高濃度藥物組,倒置顯微鏡下觀察DCs形態(tài)變化,流式細(xì)胞儀檢測DCs表面免疫分子MHC-Ⅱ、CD80表達(dá)率,酶聯(lián)免疫吸附試驗(yàn)(ELISA)檢測DCs培養(yǎng)上清液中IL-10含量,混合淋巴細(xì)胞增殖反應(yīng)(MLR)測定DCs刺激T淋巴細(xì)胞增殖能力的改變,實(shí)時定量PCR檢測PPARγmRNA表達(dá)；③免疫熒光染色法檢測藥物對TLR-4表達(dá)的影響。 結(jié)果 ①M(fèi)TT結(jié)果顯示兩種PPARγ激動劑DK2和馬來酸羅格列酮的IC50值分別為15.60±0.54μmol/L和53.8±1.94μmol/L,此時的LDH釋放率分別為16.8%和27.4%。 ②經(jīng)DK2干預(yù)后,流式細(xì)胞儀檢測DC表面MHC-Ⅱ、CD80陽性率降低,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。ELISA顯示LPS刺激后IL-10的含量增加,藥物干預(yù)后表達(dá)量進(jìn)一步增加,各組差異有統(tǒng)計(jì)學(xué)意義(P0.05)。MLR實(shí)驗(yàn)顯示隨著刺激細(xì)胞(DC)濃度下降,反應(yīng)T細(xì)胞增殖能力隨之下降,并且藥物能降低T細(xì)胞增殖能力,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。實(shí)時定量PCR結(jié)果顯示脂多糖刺激后,DCs表達(dá)PPARγmRNA略有增加,加入DK2后,PPARγmRNA表達(dá)量隨藥物濃度增加而進(jìn)一步增加,差異有統(tǒng)計(jì)學(xué)意義(P0.05),PPARγ受體拮抗劑能抑制DK2的激動作用。免疫熒光檢測示DK2抑制DCs表達(dá)TLR4。 結(jié)論 PPARγ激動劑DK2能抑制大鼠DC分化成熟及其免疫功能,抑制效率具有濃度依賴性。 目的 探討過氧化物酶體增殖物激活受體γ(Peroxisome Proliferator-Activated Receptor gamma, PPARγ)激動劑對角膜新生血管的抑制作用及機(jī)制。 方法 36只SD大鼠隨機(jī)分成A、B、C及D組,每組9只大鼠,右眼為實(shí)驗(yàn)眼。B、C、D組大鼠行角膜囊袋法制作角膜新生血管模型。A組：空白對照組,正常大鼠角膜；B：陽性對照組,制作模型后生理鹽水滴眼；C、D組：建模后分別滴用0.1%、1.0% PPARY激動劑滴眼液,均4次／d,共28d。裂隙燈顯微鏡下測量新生血管面積,Western-Blot檢測角膜血管內(nèi)皮生長因子(vascular endothelial growth factor, VEGF)表達(dá)。 結(jié)果 D組大鼠角膜新生血管面積小于陽性對照B組和C組,差異有統(tǒng)計(jì)學(xué)意義(P0.05),而C組與B組之間差異無統(tǒng)計(jì)學(xué)意義(P0.05)。Western-Blot檢測新生血管角膜表達(dá)VEGF明顯增強(qiáng),C、D組VEGF相對量有不同程度下降。結(jié)論 局部應(yīng)用PPARγ激動劑能有效抑制角膜新生血管生成,抑制VEGF的合成和分泌可能是阻止角膜新生血管生長機(jī)制的一部分。
[Abstract]:objective
The effects of the local application of the peroxisome proliferator activated receptor gamma (Peroxisome Proliferator-Activated Receptor gamma, PPAR gamma) agonist on the cornea of rats were observed to determine the drug toxicity.
Method
PPAR gamma agonist DK2 was prepared into eye drops and 0.1%, 0.5%, 1% PPAR gamma agonists were applied locally to the right eye of Wistar rats. The local changes of the eye and the staining of fluorescein sodium were observed. In accordance with the standard of eye stimulation reaction, the eye irritation was evaluated, corneal pathological tissue section staining and ELISA detection of PPAR gamma concentration in aqueous humor were carried out. Degree, comprehensive evaluation of drug safety.
Result
The score of eye stimulation reaction in each group was 1-3 points. Corneal HE and immunohistochemical staining showed that the corneal structure was intact. The concentration of PPAR gamma in aqueous humor increased significantly after the cell without injury.ELISA, and the expression of PPAR gamma was concentration dependent, but there was no statistical difference between the 0.5% and 1% groups (P0.05).
conclusion
The 1.0% concentration of PPAR gamma agonist DK2 eye drops did not irritate the eyes of mice and were safe.
objective
To investigate the effect of peroxisome proliferator activated receptor gamma (Peroxisome Proliferator-Activated Receptor gamma, PPAR gamma) agonists on corneal graft rejection in rats.
Method
SD rats were the donors and Wistar rats were the receptors, and the SD-Wistar rat model of penetrating keratoplasty was established. The rats were randomly divided into A, B, C, D and E groups, and A group: the control group was given aseptic saline eyes after operation; B group: 0.1%DK2 eye drops group; C group: oral administration group; 1% cyclosporin A (CsA)) eye drops group; group F: Wistar rats autologous gene transplantation control group, after operation physiological saline eye. After the operation, regular corneal graft was observed. 3 indexes of turbidity, edema and neovascularization were used as clinical evaluation criteria, the rejection index (RI), neovascularization index (NI), graft survival time and real-time quantitative fluorescence were recorded. The expression of ICAM-1mRNA in the cornea of rats was detected by PCR. The changes of MHC- II and CD80 in submaxillary lymph nodes were detected by flow cytometry. The expression of CD86 in the submaxillary lymph nodes of rats was detected by immunohistochemistry. The enzyme linked immunosorbent assay (ELISA) was used to detect the content of IL-10 in the aqueous humor of rats.
The average survival time of corneal graft in group A-E was 9.2 + 1.5D, 10.1 + 1.8D, 18.3 + 1.1d, 20.1 + 1.6d, 18.1 + 1.5D. The survival time of the F group was at the end of the observation period (28.0d). The survival time of the other group was compared with the A group, and the difference was statistically significant (P0.05), and there was no significant difference in the survival time 22. 0.05) the survival time of the D group was significantly different from that of the C group. The post operation 9D corneal graft ICAM-1 mRNA showed that the relative expression of A, B group was significantly higher than that of C, D, E, F group, the submandibular lymph node immunological indexes and the flow cytology results showed ninth dC. There was no obvious expression of C, D, E, F in group C, D, E, F, and C, D, E, F, and C, C, D. The average content of the aqueous humor in each group was lower, and the average content of each group was no significant difference after the operation. After ninth, the content of the rejection was delayed. A, group B increased, but the change was small.
PPAR gamma agonist can significantly prolong the survival time of corneal graft in rats, and its inhibition of corneal transplantation immune rejection has the effect of increasing concentration, and the effect is stronger than that of local drops of 1.0%DK2 eyedrops and 1% cyclosporin A.PPAR gamma agonists, which can effectively inhibit the infiltration of corneal graft and the expression of ICAM-1 mRNA. It may be a part of the anti-rejection mechanism by which dendritic cells can aggregate and present in local lymph nodes.
objective
The effects of peroxisome proliferator activated receptor gamma (Peroxisome Proliferator-Activated Receptor gamma, PPAR gamma) agonists on the differentiation, maturation and immune activity of rat bone marrow derived dendritic cells (dendritic cells, DCs) induced in vitro were investigated, and the effects of drugs on DCs expression TLR4 were investigated.
Method
The bone marrow cells of Wistar rats were induced by GM-CSF and IL-4 in vitro to differentiate into dendritic cells. (1) two different PPAR gamma agonists, DK2 and rosiglitazone, were co cultured with 12-72h, and the growth inhibition rate of dendritic cells was detected by MTT method. The efficacy of two drugs was compared with the lactate dehydrogenase assay (LDH); 2. The machine was divided into 4 groups, namely the blank control group, the positive control group (lipopolysaccharide, LPS), the low concentration drug group and the high concentration drug group. The morphological changes of DCs were observed under the inverted microscope. The flow cytometry was used to detect the DCs surface immuno molecule MHC- II, the CD80 expression rate, and the enzyme linked immunosorbent assay (ELISA) was used to detect the IL-10 content in the supernatant of DCs culture, and the mixed lymphocyte increased. The proliferation of T lymphocytes stimulated by DCs was measured by colonization (MLR), and the expression of PPAR gamma mRNA was detected by real-time quantitative PCR, and the effect of the drug on the expression of TLR-4 was detected by immunofluorescence staining.
Result
The results of MTT showed that the IC50 values of two PPAR gamma agonists DK2 and rosiglitazone were 15.60 + 0.54 mu mol/L and 53.8 + 1.94 micron mol/L respectively, and the LDH release rates were 16.8% and 27.4%., respectively.
(2) after DK2, the flow cytometry was used to detect MHC- II on the surface of DC, and the positive rate of CD80 decreased. The difference was statistically significant (P0.05).ELISA showed that the content of IL-10 increased after LPS stimulation, and the expression amount of drug dry prognosis was further increased, and the differences in each group were statistically significant (P0.05).MLR experiments showed that with the decrease of the concentration of stimulated cells (DC), the reaction T cells increased. The colonization ability decreased, and the drug could reduce the proliferation ability of T cells. The difference was statistically significant (P0.05). Real-time quantitative PCR results showed that DCs expression PPAR gamma mRNA increased slightly after lipopolysaccharide stimulation. After adding DK2, PPAR gamma mRNA expression was further increased with the increase of drug concentration, the difference was statistically significant (P0.05), PPAR gamma receptor antagonist. DK2 inhibited the expression of TLR4 in DCs by immunofluorescence assay.
conclusion
PPAR-gamma agonist DK2 can inhibit the differentiation and maturation of DC and its immune function in rats, and the inhibition efficiency is concentration-dependent.
objective
To investigate the inhibitory effect and mechanism of peroxisome proliferator activated receptor gamma (Peroxisome Proliferator-Activated Receptor gamma, PPAR gamma) agonist on corneal neovascularization.
Method
36 SD rats were randomly divided into A, B, C and D groups, 9 rats in each group, the right eye was the experimental eye.B, C, and D group rats were made corneal neovascularization model.A group: blank control group, normal rat cornea; B: positive control group, after making model physiological saline drops eye; C, D group: after modeling, 0.1%, 1% agonist drops of eye drops respectively, drop eyes after modeling respectively drops of 0.1%, 1% of agonist drops of the eye drops respectively after the model drops of eye drops respectively drip eye drops, respectively drip 0.1%, 1% of agonist drops of the eye drops respectively after the model drops of eye drops, respectively drops of the eye drops of an agonist drops of eye drops respectively after the modeling drops of 0.1%, 1% agonists drop the eye respectively after modeling A total of 4 times / D, a total of 28d. slit lamp microscope was used to measure the area of neovascularization, and the expression of corneal vascular endothelial growth factor (vascular endothelial growth factor, VEGF) was detected by Western-Blot.
Result
The area of corneal neovascularization in D group was less than that of the positive control group B and C group, the difference was statistically significant (P0.05), but there was no significant difference between the C group and the B group (P0.05), and the expression of corneal expressed in the cornea of the neovascularization was significantly enhanced by P0.05.Western-Blot, and the VEGF relative quantity of the C and D groups decreased.
Local application of PPAR gamma agonist can effectively inhibit the formation of corneal neovascularization, and inhibit the synthesis and secretion of VEGF may be part of the mechanism of inhibiting the growth of corneal neovascularization.
【學(xué)位授予單位】：華中科技大學(xué)
【學(xué)位級別】：博士
【學(xué)位授予年份】：2010
【分類號】：R779.65

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 袁偉;陸曉和;宮玉波;周瑾;;重組腺病毒載體RNA干擾阻斷ICOS共刺激通路抑制大鼠角膜移植免疫排斥反應(yīng)的研究[J];眼科新進(jìn)展;2011年08期

2 譚曉晨;朱煌;;種子細(xì)胞及支架材料在組織工程角膜構(gòu)建中的應(yīng)用(英文)[J];中國組織工程研究與臨床康復(fù);2011年32期

3 聶樹濤;;PPARγ激動劑對增生性瘢痕成纖維細(xì)胞TGF-β_1和Smad信號途徑的作用研究[J];中國美容醫(yī)學(xué);2011年07期

4 張瑋;魏桂英;;顯微鏡下自體角膜緣干細(xì)胞移植治療翼狀胬肉65例分析[J];中國誤診學(xué)雜志;2011年23期

5 王績英;王濤;;過氧化物酶體增殖因子激活受體α研究新進(jìn)展[J];中國老年學(xué)雜志;2011年12期

6 錢莉;傅奕;潘興元;田芳;龔衛(wèi)娟;季明春;;TLR3激動劑對B細(xì)胞功能的影響[J];免疫學(xué)雜志;2011年10期

7 許慈;俞麗芬;蔡劬;盧君瑤;鐘捷;;人結(jié)腸癌細(xì)胞株HCT116中雌激素受體β與mTOR基因相互作用的初步研究[J];外科理論與實(shí)踐;2011年04期

8 曾嵐;趙成正;;社會心理支持的阿片類依賴的藥物治療原則中的建議-對個體治療的建議,推薦程度和證據(jù)質(zhì)量[J];中國藥物依賴性雜志;2011年04期

9 王昭金;陳丹;張?jiān)诜?;蛋白酶活化受體4在外周痛覺信號調(diào)節(jié)作用的研究進(jìn)展[J];解剖科學(xué)進(jìn)展;2011年05期

10 肖雯;;Linaclotide治療長期便秘的兩個隨機(jī)實(shí)驗(yàn)[J];山東醫(yī)藥;2011年32期

相關(guān)會議論文 前10條

1 邱瑜;崔永耀;吳興軍;馮菊妹;劉慧中;陸陽;胡雅兒;陳紅專;;M受體重組的CHO細(xì)胞篩選M_1選擇性激動劑[A];中國藥理學(xué)會第八次全國代表大會暨全國藥理學(xué)術(shù)會議論文摘要匯編[C];2002年

2 邱瑜;崔永耀;吳興軍;馮菊妹;劉慧中;陸陽;胡雅兒;陳紅專;;M受體重組的CHO細(xì)胞篩選M_1選擇性激動劑[A];中國藥理學(xué)會第八次全國代表大會論文摘要集（第二部分）[C];2002年

3 徐萍;陳令全;姜景萍;范海清;謝勇;呂農(nóng)華;王崇文;;PPAR-γ激動劑治療對大鼠重癥急性胰腺炎生存率的影響[A];中華醫(yī)學(xué)會第七次全國消化病學(xué)術(shù)會議論文匯編（上冊）[C];2007年

4 劉紅梅;顧軍;周少娜;韓國鑫;賈娜;;強(qiáng)脈沖光IPL對皮膚成纖維細(xì)胞中SIRT1表達(dá)的影響[A];美麗人生 和諧世界——中華醫(yī)學(xué)會第七次全國醫(yī)學(xué)美學(xué)與美容學(xué)術(shù)年會、中華醫(yī)學(xué)會醫(yī)學(xué)美學(xué)與美容學(xué)分會20周年慶典暨第三屆兩岸四地美容醫(yī)學(xué)學(xué)術(shù)論壇論文匯編[C];2010年

5 陸宇斐;馬梅方;李葆明;;幼年期注射α_2-受體激動劑或拮抗劑影響小鼠成年后的空間學(xué)習(xí)[A];中國生理學(xué)會第六屆全國青年生理學(xué)工作者學(xué)術(shù)會議論文摘要[C];2003年

6 趙丁;任雷鳴;;咪唑啉受體及α_2受體非選擇性激動劑對兔離體竇房結(jié)電生理效應(yīng)的分析[A];第六屆全國藥理學(xué)教學(xué)學(xué)術(shù)會議論文摘要匯編[C];2003年

7 康誼;楊玉秀;楊修嶺;尚佳;;PPARγ激動劑對HSC-T6細(xì)胞α1(Ⅰ)膠原表達(dá)的影響[A];中華醫(yī)學(xué)會第七次全國消化病學(xué)術(shù)會議論文匯編（下冊）[C];2007年

8 龐煒;艾玎;李楠;牛小麟;李承紅;朱毅;;PPARγ激動劑通過下調(diào)可溶性表氧化物水解酶減輕心肌肥厚[A];第七屆海峽兩岸心血管科學(xué)研討會論文集[C];2009年

9 雷蕾;申竹芳;;GK和PPARγ雙靶點(diǎn)激動劑SHP—14抗糖尿病作用的研究[A];全國第十二屆生化與分子藥理學(xué)學(xué)術(shù)會議論文集[C];2011年

10 陳閩;丁兆平;;激動劑依賴的冠狀動脈舒張存在信號轉(zhuǎn)導(dǎo)通路的差異性[A];中國生理學(xué)會第六屆全國青年生理學(xué)工作者學(xué)術(shù)會議論文摘要[C];2003年

相關(guān)重要報(bào)紙文章 前10條

1 武漢大學(xué)人民醫(yī)院眼科中心主任醫(yī)師 楊燕寧;角膜移植成功率多大[N];健康報(bào);2010年

2 張健;什么時候做角膜移植最好？[N];大眾衛(wèi)生報(bào);2004年

3 特約記者 陳祖亮;人類角膜移植可望“自給自足”[N];家庭醫(yī)生報(bào);2005年

4 記者　趙宇青;四位患者眼角膜移植初步成功[N];珠海特區(qū)報(bào);2006年

5 記者楊力勇 通訊員魏妍平;角膜移植新技術(shù)可治重癥角膜盲[N];健康報(bào);2009年

6 袁松范;開發(fā)PPAR多通道激動劑須謹(jǐn)慎[N];中國醫(yī)藥報(bào);2006年

7 本報(bào)記者 陳成智邋特約記者 符壯才;角膜移植在海南步履蹣跚[N];海南日報(bào);2007年

8 陶海;角膜移植最怕組織排斥[N];衛(wèi)生與生活報(bào);2006年

9 曾凡新邋林敏;PPAR激動劑類抗糖尿病藥研發(fā)喜憂參半[N];中國醫(yī)藥報(bào);2007年

10 金亮;角膜移植：僅有愛心并不夠[N];中國醫(yī)藥報(bào);2005年

相關(guān)博士學(xué)位論文 前10條

1 鄒媛;過氧化物酶體增殖物激活受體γ激動劑抑制角膜移植免疫排斥反應(yīng)的實(shí)驗(yàn)研究[D];華中科技大學(xué);2010年

2 王強(qiáng);核受體LXR對損傷血管內(nèi)皮修復(fù)的影響及機(jī)制研究[D];第三軍醫(yī)大學(xué);2012年

3 郭惠玲;小分子化合物J2緩釋劑型藥代動力學(xué)及藥效學(xué)的實(shí)驗(yàn)研究[D];中國人民解放軍軍醫(yī)進(jìn)修學(xué)院;2010年

4 王艷;角膜上皮在角膜移植排斥反應(yīng)中作用的研究[D];復(fù)旦大學(xué);2003年

5 孟晶;應(yīng)用山茱萸總甙防治角膜移植排斥反應(yīng)的實(shí)驗(yàn)研究[D];暨南大學(xué);2003年

6 商旭敏;來氟米特活性代謝物A771726緩釋給藥系統(tǒng)抑制角膜新生血管和角膜移植免疫排斥反應(yīng)的實(shí)驗(yàn)研究[D];華中科技大學(xué);2010年

7 蔡莉;樹突狀細(xì)胞表型和功能的體外研究及其在小鼠同種異體角膜移植排斥反應(yīng)中的免疫調(diào)節(jié)作用[D];第四軍醫(yī)大學(xué);2002年

8 胡琦;轉(zhuǎn)化生長因子-β_1誘導(dǎo)角膜移植免疫耐受和抑制的研究[D];暨南大學(xué);2002年

9 王選年;β-腎上腺素受體激動劑克倫特羅的免疫特性及中毒病理學(xué)研究[D];中國人民解放軍軍需大學(xué);2002年

10 夏學(xué)巍;過氧化物酶增殖物激活受體γ激動劑治療垂體腺瘤的實(shí)驗(yàn)研究[D];中國協(xié)和醫(yī)科大學(xué);2005年

相關(guān)碩士學(xué)位論文 前10條

1 薛曉燕;再次角膜移植臨床分析[D];重慶醫(yī)科大學(xué);2012年

2 劉鑫;誘導(dǎo)性一氧化氮合成酶iNOS在大鼠穿透性角膜移植中的表達(dá)及意義[D];中國醫(yī)科大學(xué);2010年

3 姜雪來;220例角膜移植的流行病學(xué)分析[D];吉林大學(xué);2006年

4 陳江紅;LXR激動劑對動脈粥樣硬化小鼠動脈血管結(jié)構(gòu)和功能的調(diào)節(jié)作用[D];第四軍醫(yī)大學(xué);2010年

5 陳江紅;LXR激動劑對動脈粥樣硬化小鼠動脈血管結(jié)構(gòu)和功能的調(diào)節(jié)作用[D];第四軍醫(yī)大學(xué);2010年

6 陳志鈞;應(yīng)用準(zhǔn)分子激光行屈光性板層角膜移植的實(shí)驗(yàn)研究[D];南京醫(yī)科大學(xué);2003年

7 劉軍彩;前房內(nèi)免疫微環(huán)境的動態(tài)變化與角膜移植免疫排斥反應(yīng)的實(shí)驗(yàn)研究[D];青島大學(xué);2010年

8 王菲;高危角膜移植臨床觀察[D];吉林大學(xué);2006年

9 肖瓊;穿透性角膜移植的內(nèi)皮細(xì)胞變異研究[D];暨南大學(xué);2002年

10 段虎成;液氮低溫凍存對角膜抗原性影響的實(shí)驗(yàn)研究[D];大連醫(yī)科大學(xué);2004年

，

本文編號：2143678